ASLAN Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	15.52	15.31	11.32	15.31
Revenue Growth (YoY)	1.40%	35.27%	-26.07%	-
Cost of Revenue	12.64	12.22	9.9	13.8
Gross Profit	2.88	3.09	1.42	1.51
Selling, General & Admin	0.83	0.87	1.18	0.84
Operating Expenses	0.83	0.87	1.18	0.84
Operating Income	2.05	2.22	0.24	0.67
Interest Expense	-0.13	-0.15	-0.15	-0.1
Other Non Operating Income (Expenses)	0.08	-0.05	-0.09	-0.21
EBT Excluding Unusual Items	2	2.02	-0	0.37
Asset Writedown	-0.66	-	-	-
Pretax Income	1.34	2.02	-0	0.37
Income Tax Expense	0.38	0.51	0	0.1
Net Income	0.96	1.51	-0	0.27
Net Income to Common	0.96	1.51	-0	0.27
Net Income Growth	-36.21%	-	-	-
Shares Outstanding (Basic)	6	6	6	10
Shares Outstanding (Diluted)	6	6	6	10
Shares Change (YoY)	-	-	-45.00%	-
EPS (Basic)	0.18	0.27	-0.00	0.03
EPS (Diluted)	0.18	0.27	-0.00	0.03
EPS Growth	-36.21%	-	-	-
Free Cash Flow	0.7	-0.84	0.8	-1.13
Free Cash Flow Per Share	0.13	-0.15	0.15	-0.11
Gross Margin	18.58%	20.17%	12.52%	9.89%
Operating Margin	13.23%	14.51%	2.10%	4.40%
Profit Margin	6.20%	9.86%	-0.04%	1.78%
Free Cash Flow Margin	4.54%	-5.48%	7.07%	-7.41%
EBITDA	2.09	2.26	0.25	0.67
EBITDA Margin	13.46%	14.74%	2.17%	4.40%
D&A For EBITDA	0.04	0.04	0.01	0
EBIT	2.05	2.22	0.24	0.67
EBIT Margin	13.23%	14.51%	2.10%	4.40%
Effective Tax Rate	28.33%	25.28%	-	26.63%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q